• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
JFrog Ltd. - Ordinary shares
MongoDB, Inc. - Class A Common Stock
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

23.91 -4.02 (-14.39%)
Delayed Quote Updated: 2:23 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,941,926
Open 25.54
Bid (Size) 23.89 (100)
Ask (Size) 23.94 (100)
Prev. Close 27.93
Today's Range 22.68 - 25.94
52wk Range 6.690 - 34.39
Shares Outstanding 88,406,523
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate ↗
Today 12:06 EDT
Tango Therapeutics (NASDAQ:TNGX) said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for... 
Via MarketBeat
News headline image
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy
Today 6:30 EDT
From Tango Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 30.5% below 52-week high
23.91
6.6952W Low 34.3952W High
1 Week 14.5% below 1-week high
21.821W Low 27.981W High

Tango Therapeutics, Inc. - Common Stock (TNGX) traded between $6.69 and $34.39 over the past 52 weeks and last traded at $23.91, 30.5% below its 52-week high. Over the past week it ranged between $21.82 and $27.98.

Past 12 Months
+8.5%
-6.3%
-12.9%
-7.6%
+167.7%
+176.1%
1W +$1.87
1M -$1.62
3M -$3.54
6M -$1.96
YTD +$14.98
1Y +$15.25

TNGX was +176.1% over the past year, -7.6% over six months, +167.7% year to date, +8.5% in the last week.

12 Months vs Market
TNGX
+176.1%
DIA
+12.1%
SPY
+13.9%
QQQ
+16.5%
IWM
+13.3%

Over the past 12 months TNGX returned +176.1% versus DIA (Dow) +12.1%, SPY (S&P 500) +13.9%, QQQ (Nasdaq 100) +16.5% and IWM (Russell 2000) +13.3%.

Volume & Liquidity 4.07× 3-mo avg
Today 11,941,926 3-mo avg 2.9M
1W
4.0M
1M
4.0M
3M
2.9M
6M
3.5M
YTD
3.4M
1Y
3.5M

TNGX most recently traded 11,941,926 shares against a 3-month average daily volume of 2.9M.

More News

Read More
News headline image
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
October 16, 2026
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2026
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
September 01, 2026
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 11, 2026
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Executive Chair Transition
August 06, 2026
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Appoints Robert Azelby to Board of Directors
June 22, 2026
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
June 09, 2026
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Proposed $500 Million Public Offering
June 08, 2026
From Tango Therapeutics, Inc.
Via GlobeNewswire
These stocks are moving in today's session ↗
June 08, 2026
Via Chartmill
Top stock movements in today's session. ↗
June 08, 2026
Via Chartmill
These stocks are gapping in today's session ↗
June 08, 2026
Via Chartmill
Monday's pre-market session: top gainers and losers ↗
June 08, 2026
Via Chartmill
News headline image
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
June 08, 2026
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
May 29, 2026
Via The Motley Fool
News headline image
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
May 26, 2026
Via The Motley Fool
Topics Regulatory Compliance Stocks
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗
May 17, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
May 17, 2026
Via The Motley Fool
News headline image
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
May 16, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 13, 2026
From Tango Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 04, 2026
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
April 15, 2026
From Tango Therapeutics Sub, Inc
Via GlobeNewswire

Frequently Asked Questions

Is Tango Therapeutics, Inc. - Common Stock publicly traded?
Yes, Tango Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Tango Therapeutics, Inc. - Common Stock trade on?
Tango Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tango Therapeutics, Inc. - Common Stock?
The ticker symbol for Tango Therapeutics, Inc. - Common Stock is TNGX on the Nasdaq Stock Market
What is the current price of Tango Therapeutics, Inc. - Common Stock?
The current price of Tango Therapeutics, Inc. - Common Stock is 23.91
When was Tango Therapeutics, Inc. - Common Stock last traded?
The last trade of Tango Therapeutics, Inc. - Common Stock was at 10/23/26 02:23 PM ET
What is the market capitalization of Tango Therapeutics, Inc. - Common Stock?
The market capitalization of Tango Therapeutics, Inc. - Common Stock is 2.11B
How many shares of Tango Therapeutics, Inc. - Common Stock are outstanding?
Tango Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap